Tiger BioSciences Strengthens Its Wound Care Solutions via New Acquisition

Tiger BioSciences Expands Its Wound Care Capabilities through Strategic Acquisition

In a significant expansion of its regenerative medicine portfolio, Tiger BioSciences has announced the acquisition of Platelet-Rich Fibrin Matrix (PRFM) technology from Bahia Medical Inc. This advanced wound care technology is designed to enhance the treatment of chronic and complex wounds, thereby improving patient outcomes.

The PRFM system offers clinicians the ability to prepare high-quality autologous platelet concentrates directly at the point of care, a game changer for wound management. One of its most notable aspects is its versatility; the advanced dressing can adapt to a wide array of wound sizes, functioning as a wearable autologous patch. This innovative patch can receive fluid and activate PRFM in situ, streamlining the treatment process.

Oliver Burckhardt, Co-CEO of Tiger BioSciences, emphasized the importance of this acquisition, stating, "With this acquisition, we are taking another significant step toward diversifying our portfolio and committing to autologous wound care therapies." This aligns perfectly with the company’s mission to deliver market-first solutions that empower clinicians and enhance patient care.

Further enhancing Tiger BioSciences’ status in the regenerative medicine field, this addition allows the company to broaden its offerings across various healthcare settings. Garrett Grinsfelder, President of Tiger Wound Care, expressed enthusiasm about the acquisition, highlighting how it enhances the company’s ability to support healthcare providers with advanced, user-friendly tools designed to elevate the standard of care.

As part of their strategy, Tiger BioSciences is also committed to continuing the development of the newly acquired technology. This involves completing clinical trials and seeking 510(k) clearance from the FDA, with plans for a commercial launch anticipated later in 2026.

About Tiger BioSciences

Tiger BioSciences, based in Conshohocken, Pennsylvania, is a vertically integrated company dedicated to cell and tissue technologies. Their expertise spans the recovery, processing, development, and distribution of cellular, acellular, and matrix-like products, as well as aesthetic technologies. The company prides itself on being a leading tissue recovery agency and processing innovator, focused on delivering cutting-edge solutions that meet the evolving needs of healthcare providers and patients. With a steadfast commitment to enhancing patient care, Tiger BioSciences aims to provide innovative, comprehensive treatment options across a wide range of medical applications.

As the landscape of wound care technology evolves, Tiger BioSciences is well-positioned to lead the market with its latest acquisition and continued innovation in autologous therapies.

This latest move by Tiger BioSciences marks an exciting chapter in the organization’s journey, paving the way for further advancements in the critical field of wound care.